The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timeframe: From first dose to 30 days post last dose (Up to 2 months)
Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - SAD Cohorts
Timeframe: Baseline, day 1-16, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose
Number of Participants With Change From Baseline in Electrocardiograms (ECG) Intervals - MAD Cohorts
Timeframe: Baseline, Day 1-16, 2 hours pre-dose and at 7-, 24-, and 48-hours post final dose
Mean Change From Baseline in Vital Signs Part 1 - SAD Cohorts
Timeframe: Baseline and at 6-hours post-dose
Mean Change From Baseline in Vital Signs Part 1 - MAD Cohorts
Timeframe: Baseline and at 6-hours post-dose
Mean Change From Baseline in Vital Signs Part 2 - SAD Cohorts
Timeframe: Baseline and at 6-hours post-dose
Mean Change From Baseline in Vital Signs Part 2 - MAD Cohorts
Timeframe: Baseline and at 6-hours post-dose
Number of Participants With a Troponin I Increase - SAD Cohorts
Timeframe: Baseline, day 1-3, 2 hours pre-dose and at 3-, 5-, 9-, 12-, 24-, and 36-hours post-dose
Number of Participants With a Troponin I Increase - MAD Cohorts
Timeframe: Baseline, pre-dose and 7hr post dose on treatment day 1, day 2, day 5 and pre-dose and at 7-, 24-, and 48-hours post final dose
Number of Participants With Clinically Significant Laboratory Abnormalities
Timeframe: From first dose to 30 days post last dose (Up to 2 months)
Number of Participants With Clinically Significant Physical Examinations Abnormalities
Timeframe: From first dose to 30 days post last dose (Up to 2 months)